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tion of treatment efficacy and prognosis in chronic liver disease (CLD) patients. Acoustic radi-
ation force impulse imaging (ARFI) is a newly-developed transient elastography (TE) method
integrated into a conventional ultrasound machine. The study aimed to assess the performance
of ARFI imaging in the diagnosis of liver fibrosis in Taiwanese CLD patients. We also aimed to
search for the optimal cut-off values in different fibrosis stages. A total of 60 CLD patients
(40 males; mean age, 51.8 11 years) were consecutively included. They received standard
ARFI measurement within 2 weeks at the time of liver biopsy. There were eight patients with
Metavir fibrosis stage 0 (F0), 16 patients with F1, 20 patients with F2, eight patients with F3,
and eight patients with F4, respectively. The mean values among patient with F0, F1, F2, F3,
and F4 were 1.17 0.13, 1.30 0.17, 1.31 0.24, 2.01 0.45, and 2.69 0.91, respectively
(p< 0.001). The optimal cut-off ARFI value for significant fibrosis (F 2) was 1.53 with the ac-
curacy of 0.733, while it was 1.66 for advanced fibrosis (F 3) with the accuracy of 0.957. Oureclare no conflicts of interest.
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ARFI and liver fibrosis 363study demonstrated that ARFI imaging is competent for fibrosis diagnosis, particularly in CLD
patients with advanced fibrosis.
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Chronic liver disease (CLD) of various etiologies, such as
chronic hepatitis B (CHB) or chronic hepatitis C (CHC),
alcoholic liver disease, and nonalcoholic steatohepatitis
(NASH), is the leading cause of hepatocellular carcinoma
(HCC) globally. The main pathogenic mechanism underlying
hepatocarcinogenesis is necroinflammation and its subse-
quent fibrogenesis [1,2]. Therefore, severity estimation of
liver fibrosis is important for treatment efficacy, prognosis,
HCC surveillance and determining the best treatment
strategies in CLD patients [3,4].
Liver biopsy, as the gold standard method for the
assessment of liver fibrosis, is an invasive method associ-
ated with patient discomfort and sometimes with serious
complications [5,6]. Biopsy is associated with a bleeding
risk of 1% and a mortality rate of w0.01% [3,5]. Addition-
ally, liver biopsies are often considered “imperfect” sur-
rogate markers for liver fibrosis assessment because of
inherent limitations. These include invasiveness, risk of
life-threatening complications, intra- and inter-observer
variability, and sampling error.
In addition to serum biomarkers, several ultrasound-
based methods have been vigorously developed and vali-
dated for assessing the degree of fibrosis and cirrhosis by
measuring liver stiffness in the past decade. These
ultrasound-based methods shed a new light in the aspect of
noninvasive evaluation of liver fibrosis. They have provided
good diagnostic accuracy in a clinical setting [7,8]. Acoustic
radiation force impulse (ARFI) imaging is a newly-developed
transient elastography (TE) method integrated into a con-
ventional ultrasound machine and can be performed with
ultrasound probes during an abdominal ultrasound exami-
nation [8]. Previous studies have indicated that it is a good
predictor of liver fibrosis stages in CLD patients, particu-
larly in CHC patients [8,9]. However, the performance of
ARFI in Asians across different etiologies remains to be
clarified and validated.
The aim of the study was to assess the performance of
ARFI in the diagnosis of liver fibrosis in Taiwanese CLD pa-
tients. The optimal cut-off values were also evaluated ac-
cording to different fibrosis stages in a clinical basis.Methods
Patients
Between October, 2013 and November, 2014, a total of 60
CLD patients were consecutively included in this study. All
patients received a liver biopsy aiming to elucidate their
histopathological manifestations in a clinical setting. The
Ethics Committee of Kaohsiung Medical University Hospital,Kaohsiung, Taiwan, approved the study before it began.
The study was conducted according to the Declaration of
Helsinki. Written informed consent for anthropomorphic
measurements, ARFI measurement, blood sampling, and
medical record review were obtained from patients prior to
enrollment.
ARFI measurement
ARFI measurement was performed with curved-array
transducer (6CI probe) of the Siemens ACUSON S2000 ul-
trasound system (Siemens Medical Solutions, Erlangen,
Germany). The 10 mm 5 mm region of interest was
focused on the right liver lobe via an intercostal approach.
All patients were measured on the right lobe at a depth of
w2e3 cm below the capsule during relaxed breath-holding.
Food intake increased shear wave values significantly,
especially when consumed< 3 hours prior to measure-
ments. Therefore all patients had enough fasting time (> 10
hours). The mean shear wave velocity (m/s), standard de-
viation, and number of effective measurements were
recorded. At least 10 successful acquisitions were
measured for each patient.
ARFI-failure was defined as no successful ARFI mea-
surement after 10 attempts and an interquartile range
greater than 30%. The interquartile range is defined as the
difference between the 75th percentile, essentially the
range of the middle 50% of the data.
Histology grading and staging
Liver biopsy was performed within 2 weeks of ARFI mea-
surement using an echo-assisted method. For each patient,
a liver biopsy specimen of at least 1.5 cm in length was
taken and fixed in 10% formalin buffer. Biopsy samples were
stained with hematoxylin-eosin and the results were then
reported by a dedicated liver pathologist blinded to each
patient.
Histological grading was performed based on the histo-
logical activity index (HAI) by Knodell et al. [10]. Fibrosis
score (F0eF4) was determined according to the Metavir
scoring systems [11]. Significant fibrosis and advanced
fibrosis are defined as F2, and F3e4, respectively.
Statistical analyses
The demographic data were expressed as mean values -
standard deviation (SD). ARFI results were expressed as
mean values SD and were compared between groups
using analysis of variance. The diagnostic performances of
ARFI in the diagnosis of fibrosis stages were evaluated by
receivereoperator characteristic (ROC) curves. The area
Figure 1. The calculated cut-off value and AUROC areas of
ARFI elastometry were F3e4 cut-off valueZ 1.66,
AUROCZ 0.957;  F2 cut-off valueZ 1.53, AUROCZ 0.733; 
F1 cut-off valueZ 1.44, AUROCZ 0.804. ARFIZ Acoustic
radiation force impulse imaging; AUROCZ area under the
receivereoperator characteristic curves.
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terval were used as indexes of accuracy. All statistical an-
alyses were based on two-sided hypothesis tests with a
significance level of p< 0.05. Quality control procedures,
database processing, and analyses were performed using
SPSS version 15.0 (SPSS Inc., Chicago, IL, USA).
Results
A total of 60 CLD patients (40 males; mean age, 51.8 11
years) were consecutively investigated. There were four
patients in the CHB group, 67 patients in the CHC group,
and 10 patients in the NASH group, respectively. All ARFI
measurements were successfully achieved. There were
eight patients with a score of F0, 16 patients with F1, 20
patients with F2, eight patients with F3, and eight patients
with F4, respectively (Table 1).
The mean ARFI measurement value among all patients
was 1.57 0.64. The mean values among F0, F1, F2, F3, and
F4 were 1.17 0.13, 1.30 0.17, 1.31 0.24, 2.01 0.45,
and 2.69 0.91, respectively (p< 0.001; Figure 1). The
optimal cut-off ARFI value for significant fibrosis (F 2) was
1.53. The sensitivity, specificity, positive predictive value,
negative predictive value, and the accuracy were 0.528,Table 1 Basic demographical and clinical features of the
patients.
nZ 60
Age (y) 51.8 (11.0)
Sex. n (%)
Male 40 (67)
Female 20 (33)
Etiology n (%)
HBV 3 (5)
HCV 47 (78)
NASH 10 (17)
Body weight (kg) 72.8 (12.0)
BMI (kg/m2) 26.7 (3.5)
WBC (/mL) 5742.9 (1616.2)
Hb 14.3 (1.5)
Platelet (1000/mL) 178.6 (61.2)
AST (IU/L) 68.7 (57.2)
ALT (IU/L) 92.1 (72.0)
Bilirubin 1.1 (0.4)
Alkaline-P 104.3 (107.3)
Albumin 4.3 (0.4)
Creatinine 0.8 (0.2)
Fibrosis stage, n (%)
F0 8 (13)
F1 16 (27)
F2 20 (33)
F3 8 (13)
F4 8 (13)
Data are presented as mean standard deviation, unless
otherwise indicated.
ALTZ alanine aminotransferase; ASTZ aspartate aminotrans-
ferase; BMIZ body mass index; FZMetavir fibrosis stage;
HBVZ hepatitis B virus; HCVZ hepatitis C virus; NASHZ no-
nalcoholic steatohepatitis; WBCZwhite blood cell.0.958, 0.950, 0.575, and 0.733, respectively. The optimal
cut-off ARFI value for advanced fibrosis (F 3) was 1.66.
The sensitivity, specificity, positive predictive value,
negative predictive value, and the accuracy were 0.875,
0.977, 0.933, 0.956, and 0.957, respectively (Table 2).
Discussion
Liver fibrosis is the final result of liver injury of various
etiologies. The assessment and prediction of liver fibrosis
severity is important in therapeutic decision-making and in
prognosis prediction of CLD. Liver biopsy, regarded as the
gold standard in this aspect for decades, has been chal-
lenged by many newly-developed noninvasive tools in the
past decade. Our study demonstrated that ARFI imaging is a
competent diagnostic tool for the diagnosis of fibrosis,
particularly for the diagnosis of advanced fibrosis in
Taiwanese CLD patients. The optimal cut-off values found
in this study are therefore proven for clinical use in the
Asian population.
Precise measurement of the fibrotic lesion is important.
First, progressive fibrosis is believed to predict progression
to cirrhosis and/or HCC, particularly in CLD patients [12].
The fibrosis stage may predict the likelihood of response toTable 2 Diagnostic performance, optimal cut-offs, and
validity of ARFI for the diagnosis of liver fibrosis.
Optimal
cut-off
Sensitivity Specificity PPV NPV Accuracy
F0 1.20 0.712 0.75 0.949 0.286 0.717
F1 1.32 0.596 0.875 0.969 0.25 0.633
F2 1.53 0.528 0.958 0.95 0.575 0.733
F3 1.66 0.875 0.977 0.933 0.956 0.957
F4 1.98 0.583 0.904 0.583 0.904 0.9
ARFIZ Acoustic radiation force impulse imaging; NPVZ neg-
ative predictive value; PPVZ positive predictive value.
ARFI and liver fibrosis 365antiviral therapeutic interventions in CLD patients [3,13]. In
addition, a stage of significant fibrosis implies that an
aggressive therapeutic approach is needed for the amelio-
ration of fibrosis progression. Surveillance of portal hyper-
tension such as portal pressure measurement and varices
evaluation with esophagogastric endoscope examination is
indicated in CLD patients with advanced fibrosis [14]. Our
results were in accordance with a previous pooled meta-
analysis of ARFI, which reported diagnostic accuracies of
0.93 for the diagnosis of liver cirrhosis, 0.91 for the diag-
nosis of severe fibrosis and 0.87 for the diagnosis of signif-
icant fibrosis [15].
ARFI has been developed as a sonographic-based
method involving the mechanical excitation of tissue
using short-duration acoustic pulses. These produce prop-
agation of shear waves, generating localized minute dis-
placements in the tissue. The shear wave velocity
measured in a region of interest is smaller than that of
other TE methods [16]. The major advantage of this
technology is that it can be easily implemented on a
modified commercial sonographic machine. Previous
studies have indicated that its performance was compa-
rable to other TE-based methods, such as FibroScan, in
CHC patients [15,17]. In addition, ARFI is easily performed
and is rarely failed technically, giving it a promising
advantage in clinical application.
Despite the fact that TE-based methods provide good
diagnostic accuracy, characteristics that limit the use of TE
include the high cost of the equipment, the need for reg-
ular recalibration, trained operators, and the lack of vali-
dated cut-off values for specific fibrosis stages. However,
the performance of ARFI might be limited by the narrow
range of values. Therefore, validation across different
races with CLD is needed to acquire the regional and/or
racial optimal cut-off values in clinical practice. Our results
further addressed the concern that the narrow metrics of
ARFI measurement might undermine its performance. The
other limitation of the study was the somewhat heteroge-
neous composition of the patients, particularly the limited
CHB patients. Lack of other noninvasive tools for compari-
son also limited the clinical application of our results.
Meanwhile, whether a high alanine aminotransferase level
affects the performance of sonography-based methods re-
mains to be elucidated [18]. The point might not be fully
clarified with the limited patient numbers in the study.
Further collaborative study with other developing nonin-
vasive tools is needed to gain a wider spectrum of valida-
tion to compensate for this disadvantage.
In conclusion, the current study demonstrated that ARFI
imaging is a good diagnostic tool for noninvasive liver
fibrosis assessment, particularly for the diagnosis of
advanced fibrosis in CLD patients. The study also provided
the optimal cut-off values for clinical use in the Asian
population. Further studies to validate the TE-based
methods across different etiologies in different regions
and races are needed.Acknowledgments
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